Medical/Pharmaceuticals
Pioneering Global Presence, Empowering the World - Zuowei Technology Shining at WHX Miami Medical Expo
SHENZHEN, China, July 1, 2025 /PRNewswire/ -- From June 11 to 13, the 2025 WHX Miami Medical Expo (formerly known as FIME), the annual grand event of the medical industry in the Americas, was held at theMiami Beach Convention Center. As one of the largest and most influential professional exhibit...
2025-07-01 16:32
2317
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach
TAIPEI and SHANGHAI and SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major out-licensing agreement with Shanghai He...
2025-07-01 13:40
2211
Wingderm USA Takes the Lead at TAS 2025, Cementing Its Local Presence in the U.S.
BEIJING, June 30, 2025 /PRNewswire/ -- Wingderm®, a leading innovator in energy-base medical aesthetic technologies, officially made its debut at The Aesthetic Show (TAS) 2025, held fromJune 27 to 29 in Las Vegas. This marks a key step as the brand grows in the U.S. medical aesthetic market. A...
2025-07-01 00:35
2100
Noul Publishes Its Fifth Sustainability Report, Outlining a Vision for Growth and a Decade of Breakthroughs
* "The next decade will focus on securing strong growth momentum by strengthening product competitiveness and profitability" * First technology-special listed company to join the Corporate Value-Up Program… "We will grow by faithfully responding to stakeholder needs and expectations." YONGIN,...
2025-06-30 21:00
2315
Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline
Interim analysis planned for January 2026 with final trial results in late 2026 Highlights: * With the 100th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed forJanuary 2026 and the timeline for final results reconfirmed for late 2026 * An...
2025-06-30 20:30
1844
Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals
TOKYO, June 30, 2025 /PRNewswire/ -- Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc. ("Curadh") announced plans to enter a strategic partnership, including a Joint Venture to broadly advance the global development of Astatine-211 (At-211) based radiopharmaceuticals. The collaboration co...
2025-06-30 20:00
1855
WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL
* The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL * It reduces viscosity by up to 90% while maintaining formulation stability and injectability SHANGHAI, June 30, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), ...
2025-06-30 19:00
3976
Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2025-06-30 12:04
2575
Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection
SHANGHAI, June 27, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection (R&D code: 8MW0511).Under the t...
2025-06-27 22:00
3789
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management
SAN FRANCISCO and SUZHOU, China, June 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...
2025-06-27 17:49
2985
Drug-Free Nasal Spray LUCA V-Defense Creates a Protective Shield Against Viruses and Allergies
SEOUL, South Korea, June 27, 2025 /PRNewswire/ -- As respiratory illnesses like COVID-19, influenza, and Mycoplasma pneumonia continue to spread, the need for safe, non-pharmaceutical prevention options is growing. South Korea–based biotech firm LUCA AICELL has developed LUCA V-Defense Nasal Spra...
2025-06-27 16:07
2098
TransThera Publishes Translational Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Annals of Oncology
NANJING, China and GAITHERSBURG, Md., June 27, 2025 /PRNewswire/ -- TransThera Sciences Inc. ("TransThera") announced that the translational studies of tinengotinib in CCA with acquired resistance to FGFR inhibitors were published inAnnals of Oncology (IF 56.7). Dr. Peng Peng, Vice President at T...
2025-06-27 14:26
2170
MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY
* In the study of rare diseases and precision medicine, understanding gene expression in the spatial context of tissues is essential. High-throughput sequencing and STOmics technology will enhance biological and molecular understanding of various pathologies. MILAN, June 26, 2025 /PRNewswire/ -...
2025-06-27 10:46
2307
WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity
SHANGHAI, June 26, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is delighted to announce that its Nantong site (Phase I) has been recognized as the Popula...
2025-06-27 08:00
2902
NEW SINGAPORE STUDY TO ASSESS GROWING PREVALENCE AND IMPACT OF FOOD ALLERGIES
Landmark four-year joint study led by NUH and NUS Medicine, in collaboration with KKH, NUP and SSHSPH, is the first and largest to involve over 2,000 children in addressing food allergies SINGAPORE, June 26, 2025 /PRNewswire/ -- A group of clinicians and researchers from theNational University H...
2025-06-26 23:32
2904
SineuGene's SNUG01 Receives FDA Orphan Drug Designation for ALS
BEIJING, June 26, 2025 /PRNewswire/ -- SineuGene Therapeutics, a clinical-stage biotechnology company focused on gene therapies for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its gene therapy, SNUG01, for the trea...
2025-06-26 22:04
2042
Ubie Announces Cumulative Total Funding of Over $125M as US Efforts Target Expansion into Generative AI and Provider Solutions
* Ubie's growth has been accelerated by recent strategic investment and acceptance into Mayo Clinic Platform Accelerate program * Ubie's US Symptom Checker platform has seen 85% organic growth and a total user base of 4 million, helping deliver partnerships across patient advocacy and life sc...
2025-06-26 21:00
2759
Porton Advanced and EVA Pharma Sign MOU to Expand CAR T-Cell Therapy Access in The Middle East and Africa
A new era of personalized gene therapy for Leukemia patients in Egypt, Saudi Arabia, and beyond. SUZHOU, China and CAIRO, June 26, 2025 /PRNewswire/ -- Porton Advanced Solutions, a global leading cell and gene therapy CDMO service provider, andEVA Pharma, one of the leading pharmaceutical compan...
2025-06-26 21:00
2034
Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia
SHANGHAI, June 26, 2025 /PRNewswire/ -- Alebund Pharmaceuticals
2025-06-26 20:00
1960
BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria
* Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has ...
2025-06-26 08:38
8281
Week's Top Stories
Most Reposted
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 327 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 308 media titles]
2026-02-26 19:57
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 308 media titles]
2026-02-26 09:30
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 302 media titles]
2026-02-24 16:13
Most Read
/C O R R E C T I O N -- Republic Power Group Limited (NASDAQ: RPGL)/
2026-02-20 06:36
9480
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
2026-02-20 07:27
8694